Ultimovacs ASA: Pioneering AI-Driven Cancer Immunotherapy for a Brighter Tomorrow
In the rapidly evolving landscape of cancer therapy, Ultimovacs ASA stands at the forefront, leveraging cutting-edge AI technology to develop innovative immunotherapies aimed at combating cancer. With their lead product candidate, UV1, Ultimovacs is driving progress in the field of cancer immunotherapy by inducing a specific T cell response against the universal cancer antigen, telomerase….